Eisai CoSTU:EII +0.24%74 EBITDA Margin % is 1.75% as of Mar. 2026, which is 87% below its 10-year median of 13.91. GuruFocus rates STU:EII with a GF Score™ of 74/100 and a GF Value™ of €30.90 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, Eisai Co ranks worse than 51.62% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Eisai Co's EBITDA for the
three
months ended in Mar. 2026 was €20 Mil. Eisai Co's Revenue for the
three
months ended in Mar. 2026 was €1,120 Mil. Therefore, Eisai Co's EBITDA margin for the quarter that ended in Mar. 2026 was 1.75%.
Eisai Co (STU:EII) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Eisai Co EBITDA Margin % Related Terms
Eisai Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Eisai Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Eisai Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eisai Co (STU:EII) has a EBITDA Margin % of 1.75% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Eisai Co and its competitors. This is 87% below median its historical median of 13.91. Over the past decade, Eisai Co's EBITDA Margin % has ranged from 11.62 to 23.46. According to the industry distribution chart, Eisai Co ranks #493 out of 955 companies in the Drug Manufacturers industry, placing it in the top 51.6%.
Is Eisai Co's EBITDA Margin % too high?
Eisai Co's current EBITDA Margin % of 1.75% is 87% below median its 10-year median of 13.91. Over the past 10 years, this metric has ranged from a low of 11.62 to a high of 23.46. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Eisai Co's value of 1.75% is 85.9% below this industry median. Based on the distribution chart, Eisai Co ranks #493 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eisai Co has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #493 out of 955 companies for EBITDA Margin %. This places Eisai Co in the lower half of its industry. The industry median EBITDA Margin % is 12.39. Eisai Co's value of 1.75% is 85.9% below this benchmark. Historically, Eisai Co's own EBITDA Margin % has ranged from 11.62 to 23.46 over the past decade. While the company's 10-year median is 13.91 vs. the industry median of 12.39, Eisai Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eisai Co's current EBITDA Margin % of 1.75% is 85.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Eisai Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current EBITDA Margin % is 1.75%, which is 87% below median its own 10-year median of 13.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (STU:EII) is currently considered Significantly Undervalued. The stock's GF Value™ is €30.90, compared to a current price of €21.11 — trading 31.7% below its estimated fair value. The current EBITDA Margin % is 1.75%, which is 87% below median its 10-year median of 13.91 and 85.9% below the Drug Manufacturers industry median of 12.39. Eisai Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Eisai Co (STU:EII), the current EBITDA Margin % is 1.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (STU:EII) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of €21.11 is trading 31.7% below its estimated GF Value™ of €30.90.
GuruFocus considers Eisai Co to be Significantly Undervalued.
Key valuation signals for STU:EII:
EBITDA Margin %: 1.75% (87% below median its 10-year median of 13.91)
GF Value™: €30.90 vs. price of €21.11 (31.7% below fair value)
Industry Position: 85.9% below the Drug Manufacturers median (#493 of 955)
No single metric tells the full story. See the STU:EII stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
74GF Score
Get the complete analysis for STU:EII
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:EII has been successfully added to your 
